An Austrian study on 70 men with biopsy-proven prostate cancer found that PET/CT using F18 fluorocholine had 79% sensitivity, 97% specificity and 84% accuracy in identifying the patients with bone metastases. Of the 262 lesions that showed increased uptake in the study, 210 were determined to be bone metastases. The findings point to the potential of FCH-PET/CT in early diagnosing of bone metastases in prostate cancer patients.

Full Story:

Related Summaries